JP2024518710A - 可溶性封入ポリヌクレオチドとイオン化可能脂質とを含むポリマーソームならびにその作製および使用方法 - Google Patents

可溶性封入ポリヌクレオチドとイオン化可能脂質とを含むポリマーソームならびにその作製および使用方法 Download PDF

Info

Publication number
JP2024518710A
JP2024518710A JP2023562483A JP2023562483A JP2024518710A JP 2024518710 A JP2024518710 A JP 2024518710A JP 2023562483 A JP2023562483 A JP 2023562483A JP 2023562483 A JP2023562483 A JP 2023562483A JP 2024518710 A JP2024518710 A JP 2024518710A
Authority
JP
Japan
Prior art keywords
polymersome
seq
immune response
antigen
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518710A5 (cg-RX-API-DMAC10.html
Inventor
マドハバン ナラーニ
ジェン ハン ラム
リアム マーティン
シュリーニバース ベンカタラマン
テック ワン キア
Original Assignee
エイシーエム バイオラブズ プライベート リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイシーエム バイオラブズ プライベート リミテッド filed Critical エイシーエム バイオラブズ プライベート リミテッド
Publication of JP2024518710A publication Critical patent/JP2024518710A/ja
Publication of JP2024518710A5 publication Critical patent/JP2024518710A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023562483A 2021-04-12 2022-04-12 可溶性封入ポリヌクレオチドとイオン化可能脂質とを含むポリマーソームならびにその作製および使用方法 Pending JP2024518710A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21167911 2021-04-12
EP21167911.3 2021-04-12
PCT/EP2022/059701 WO2022218957A1 (en) 2021-04-12 2022-04-12 Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof

Publications (2)

Publication Number Publication Date
JP2024518710A true JP2024518710A (ja) 2024-05-02
JP2024518710A5 JP2024518710A5 (cg-RX-API-DMAC10.html) 2025-04-21

Family

ID=75786882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562483A Pending JP2024518710A (ja) 2021-04-12 2022-04-12 可溶性封入ポリヌクレオチドとイオン化可能脂質とを含むポリマーソームならびにその作製および使用方法

Country Status (8)

Country Link
US (1) US20250281405A1 (cg-RX-API-DMAC10.html)
EP (1) EP4322922A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024518710A (cg-RX-API-DMAC10.html)
CN (1) CN117440798A (cg-RX-API-DMAC10.html)
AU (1) AU2022258552A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023021224A2 (cg-RX-API-DMAC10.html)
CA (1) CA3214934A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022218957A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250381150A1 (en) 2024-03-08 2025-12-18 Genzyme Corporation Lipid nanoparticles
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof
WO2026142951A1 (en) 2024-12-23 2026-07-02 Genzyme Corporation Pharmaceutical system

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019145475A2 (en) * 2018-01-25 2019-08-01 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625A (en) 1848-06-13 Machinery for cutting and punching copper sheathing
US569825A (en) 1896-10-20 John h
US70185A (en) 1867-10-29 fan oh be
US5545A (en) 1848-05-02 Improvement in machinery for separating gold
US807A (en) 1838-06-27 Samuel gilson
US567A (en) 1838-01-09 Machine for r-uibbii
US980A (en) 1838-10-13 Improvement in the mode of hardening or chilling the hubs of car and other wheels
US4816A (en) 1846-10-17 Bell machinery for hotels
US669A (en) 1838-04-02 In the manufacture of gunpowder
US2003A (en) 1841-03-12 Improvement in horizontal windivhlls
US16A (en) 1836-08-31 Edwin m
US4676A (en) 1846-07-31 roller
US5591A (en) 1848-05-23 Pump fob
US5661A (en) 1848-07-11 Boring and mortising machine
US633425A (en) 1899-01-26 1899-09-19 Louis Henry Clyborne Wire-tightener.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
US10364350B2 (en) 2009-04-20 2019-07-30 Agency For Science, Technology And Research Vesicular system and uses thereof
WO2012018306A1 (en) 2010-08-05 2012-02-09 Agency For Science, Technology And Research A multicompartmentalized vesicular structure and a method for forming the same
CA3170184A1 (en) 2012-03-12 2013-09-19 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
CN111450060A (zh) 2012-11-19 2020-07-28 新加坡科技研究局 用于引发对免疫原的免疫响应的方法
EP2898894A1 (en) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-micro particles for intradermal delivery
WO2016154432A1 (en) 2015-03-24 2016-09-29 VaxLiant, LLC Adjuvant compositions and related methods
EP3162361A1 (en) * 2015-11-02 2017-05-03 Universität für Bodenkultur Wien Improved magnetically reactive vesicular bodies
WO2020058239A1 (en) * 2018-09-18 2020-03-26 Universiteit Gent Therapeutic nanoparticles and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019145475A2 (en) * 2018-01-25 2019-08-01 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof

Also Published As

Publication number Publication date
CA3214934A1 (en) 2022-10-20
BR112023021224A2 (pt) 2024-01-16
WO2022218957A1 (en) 2022-10-20
EP4322922A1 (en) 2024-02-21
US20250281405A1 (en) 2025-09-11
AU2022258552A1 (en) 2023-10-19
CN117440798A (zh) 2024-01-23

Similar Documents

Publication Publication Date Title
JP7542257B2 (ja) 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法
JP7676030B2 (ja) 関連づけられた抗原を有するポリマーソームの集団を、関連づけられたアジュバントを有するポリマーソームの集団と一緒に投与することによって、免疫応答を誘発する方法、およびそれら2つのポリマーソーム集団を含む組成物
US20250281405A1 (en) Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
JP2019033743A (ja) インターロイキン−21ムテイン及び治療方法
JP2022552552A (ja) 活性薬剤または治療剤の送達のための水中油型エマルジョン製剤
US20220105176A1 (en) Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
JP7127021B2 (ja) 細胞傷害性粒子
JP2025508798A (ja) 脂質とブロックコポリマーとを含むポリマー-脂質ハイブリッドナノ粒子ならびにその作製方法および使用方法
US20230398207A1 (en) Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
US20240108720A1 (en) Sole use of polymersome associated adjuvant for stimulating an immune response
US20230381309A1 (en) Methods of treating diffuse large b-cell lymphoma
EP4255460A1 (en) Method of sensitizing cancers to immunotherapy using immunomodulatory agents
WO2024186623A1 (en) Methods of making dried pharmaceutical compositions
WO2025257329A2 (en) Fusion polypeptide and liponanoparticle comprising the same
WO2024186646A1 (en) Methods of making lipid adjuvanted compositions
WO2023083868A1 (en) Tlr7 agonist and combinations for cancer treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250411

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260518

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260721

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260722